Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocular photodynamic therapy

This article was originally published in The Gray Sheet

Executive Summary

Coverage review initiated by HCFA July 26 could lead to a national Medicare coverage decision for QLT PhotoTherapeutics' Visudyne (verteporfin) to treat age-related macular degeneration (AMD). Marketed by Novartis' Ciba Vision eye care unit, Visudyne is an intravenous photosensitizing drug that is activated by a laser. Coherent, Inc. and Zeiss Humphrey Systems have competed in the AMD laser market since Visudyne's FDA approval April 13
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel